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Abstract
Purpose of Review—Anaphylaxis is a rare, serious hypersensitivity reaction following 
vaccination, which is rapid in onset and characterized by multisystem involvement. Although 
anaphylaxis may occur after any vaccine, understanding the risk for this outcome, particularly 
following influenza vaccines, is important because of the large number of persons vaccinated 
annually. Recent Findings Two recent CDC safety studies confirmed the rarity of post-vaccination 
anaphylaxis. In a 25-year review of data from the Vaccine Adverse Event Reporting System 
(VAERS), reports in children were most common following childhood vaccinations and among 
adults more often followed influenza vaccine. In a Vaccine Safety Datalink (VSD) study, the 
estimated incidence of anaphylaxis was 1.3 per million vaccine doses administered for all vaccines 
and 1.6 per million doses for IIV3 (trivalent) influenza vaccine.
Summary—Despite its rarity, its rapid onset (usually within minutes) and potentially lethal 
nature require that all personnel and facilities providing vaccinations have procedures in place for 
anaphylaxis management.
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Anaphylaxis
Anaphylaxis is an acute, systemic, and potentially life-threatening hypersensitivity reaction 
with multiple organ system involvement [1]. In the USA, the rate of anaphylaxis from all 
causes is as high as 100 cases per 100,000 population and is associated with as many as 
1,000 deaths per year [2]. The major systems involved include the skin, cardiovascular, 
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respiratory, and gastrointestinal systems with common symptoms being a generalized 
urticarial rash, airway swelling and difficulty breathing, hypotension and nausea and 
vomiting [2–5]. In a specific individual, the severity and type of symptoms experienced may 
vary depending upon the predominant system(s) affected. The underlying pathophysiologic 
mechanism is the sudden release of pre-formed mediators (histamine and others) contained 
in mast cell and basophil granules into the systemic circulation. This rapid “degranulation” 
occurs most often in individuals sensitized by a prior exposure to an antigen, where that 
exposure leads to the production of IgE antibodies, which bind to the surface of the mast 
cells and basophils [3–5]. A subsequent exposure to the same antigen (now allergen) 
precipitates the degranulation process. Less commonly, degranulation due to non-
immunologic mechanisms can also occur (e.g., certain drugs acting directly on mast cells). 
Many different potential allergenic exposures have been associated with the development of 
IgE-mediated anaphylaxis including food (e.g., milk, eggs, peanuts, shellfish, gelatin), food 
additives (e.g., yeast), venoms (e.g., insect stings), environmental exposures (e.g., grass 
pollen), latex (e.g., surgical gloves), diagnostic reagents (e.g., radiographic contrast media), 
drugs (e.g., antibiotics, nonsteroidal anti-inflammatory drugs), and immunizations [1–6].
Hypersensitivity reactions following vaccination are not uncommon; however fortunately, 
these are often non-serious, and in many instances, they may not be immunologically 
mediated and not reproducible on re-exposure [6, 7, 8•, 9•]. Serious post-vaccination 
immunologically mediated reactions, including anaphylaxis, are exceedingly rare. However, 
virtually all vaccines have the potential to trigger these outcomes [10]. In a patient with 
vaccine-associated, potentially immunologically mediated, hypersensitivity, it is important to 
identify the mechanism of the reaction. If there is confirmation of acute hypersensitivity, and 
the patient is required to receive a further vaccine dose(s), desensitization to the vaccine may 
be undertaken or, in a low-risk individual, the vaccine may be administered in split doses 
(one-tenth of the dose and then nine-tenths of the dose) [6].
Vaccine Components Known to Cause Hypersensitivity
In addition to the active component (the antigen) which induces the immune response, other 
potentially allergenic vaccine constituents include residual animal protein, antimicrobial 
agents, preservatives, stabilizers, adjuvants, and other components [6, 7, 8•, 9•]. Individual 
vaccine ingredients implicated in causing acute vaccine reactions include egg protein, 
gelatin, milk proteins, and other additives and trace compounds remaining from the 
manufacturing process. Natural rubber latex, which may be in the syringe plunger, the tips of 
pre-filled syringes and vaccine vial stoppers, is another potential trigger for anaphylaxis [6, 
7, 8•, 9•]. The manufacturer’s package insert for each of the currently available US licensed 
vaccines may be found on the FDA website at https://www.fda.gov/BiologicsBloodVaccines/
Vaccines/ApprovedProducts/ucm093833.htm and lists the amount and the purpose of each 
excipient and media substance contained in the vaccine. This information is consolidated in 
the CDC Pink Book Vaccine Excipient and Media Summary (excipients included in US 
vaccines, by vaccine summary table available at https://www.cdc.gov/vaccines/pubs/
pinkbook/downloads/appendices/b/excipient-table-2.pdf
McNeil Page 2
Curr Treat Options Allergy. Author manuscript; available in PMC 2020 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
There are several recent published reviews detailing the role of different excipients and 
media in vaccines, which have the potential to cause hypersensitivity reactions including 
anaphylaxis [6, 7, 8•, 9•]. This review will not discuss these further with the exception of 
egg protein, which has been of concern recently with influenza vaccines and stimulated 
revised recommendations from the CDC’s Advisory Committee on Immunization Practices 
(ACIP)
Egg allergy is the most frequent type of food allergy among children with sensitizations 
occurring particularly in children before 5 years of age. Exposure to commonly used 
vaccines that contain small amounts of residual egg protein (ovalbumin) from the vaccine 
manufacturing process has been of concern as a possible cause of acute onset 
hypersensitivity reactions, including anaphylaxis. Ovalbumin concentration in vaccines is 
not always reported and can vary among vaccine brands and batches. Concentrations are 
usually higher in vaccines cultured on embryonic chicken eggs (influenza, yellow fever, and 
rabies) and lower in vaccines cultured on fibroblasts of chicken embryos (measles, mumps, 
and rubella vaccine [MMR; Merck, Whitehouse Station, NJ]) [6, 7, 8•, 9•]. Most of the 
studies that have assessed the safety of vaccines containing egg proteins in patients with egg 
allergy have evaluated the influenza vaccines.
Influenza Vaccine and Egg Allergy
Following the 2010 recommendations by the ACIP for universal annual influenza 
vaccination of all persons older than 6 months of age [10], the total number of influenza 
doses distributed in the USA has steadily increased up to approximately 155 million in the 
2017–2018 season (the last season with complete data) (https://www.cdc.gov/flu/
professionals/vaccination/vaccinesupply.htm). This dramatic increase in vaccination 
coverage recently prompted increased concern for rare vaccine adverse events including 
acute hypersensitivity and anaphylaxis resulting from egg protein contained in certain 
influenza vaccines. A review of recently available evidence from several studies in the 
medical literature has shown that severe allergic reactions to the currently available egg-
based vaccines in persons with egg allergy are rare, and therefore, the ACIP has modified its 
recommendations for these individuals. The current 2018–2019 recommendations for 
influenza vaccination of persons with allergies state that persons with a history of egg 
allergy of any severity may receive any licensed, recommended, and age-appropriate 
influenza vaccine including inactivated influenza vaccine (IIV), quadrivalent recombinant 
influenza vaccine (RIV4), or quadrivalent live attenuated influenza vaccine (LAIV4) [11••]. 
However, persons with a history of severe allergic reaction to egg should be vaccinated in a 
medical setting and the vaccine administration supervised by a health care provider able to 
recognize and manage severe allergic conditions. Despite there being no specific post-
vaccination observation period recommended for egg-allergic persons, the ACIP’s General 
Best Practice Guidance (https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/
index.html) advises providers to consider observing vaccinees for 15 minutes following any 
vaccine administration to lessen the risk of injury should syncope occur. While the ACIP 
recommendation reflects official CDC policy, the guidance provided by the American 
Academy of Pediatrics (AAP) for the 2018–2019 season is a more general policy, which 
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states that children with egg allergy can receive influenza vaccine with no additional 
precautions than those considered for any vaccine [12].
Recent CDC Anaphylaxis Surveillance and Research Studies
Before discussing specific studies on anaphylaxis, a brief overview of the CDC vaccine 
safety infrastructure and the standard Brighton Collaboration case definition used in these 
studies is in order.
The CDC Vaccine Safety Infrastructure
Vaccines, like other pharmaceutical products, undergo extensive safety and efficacy 
evaluations in the laboratory, in animals, and in sequentially phased human clinical trials 
(Fig. 1). Initial human studies, referred to as phase 1, are safety and immunogenicity studies 
performed in a small number of closely monitored subjects. Phase 2 studies are dose-ranging 
studies, which may enroll up to a few hundred subjects. Finally, phase 3 trials typically 
involve many thousands of individuals and may require several years to complete; however, 
these provide critical documentation of the vaccine’s effectiveness and important additional 
safety data required for licensing. Following successful completion of all three phases of 
clinical development, the vaccine manufacturer submits a biologic license application (BLA) 
to the FDA. Consideration of the BLA by the FDA involves review by a multidisciplinary 
expert panel of the efficacy and safety information from the clinical trials, to inform a risk/
benefit assessment and to make a recommendation (or not) for approval of the vaccine. As 
part of the overall evaluation, the FDA also reviews the product labeling, the manufacturing 
facility, and the manufacturing protocols. However, following successful approval by the 
FDA, the agency continues to oversee the production of the vaccine to ensure continuing 
safety. In addition, many vaccines undergo phase 4 studies sponsored by the manufacturer, 
which are formal studies conducted once the vaccine is on the market.
Following licensing, the ACIP makes specific recommendations for the incorporation of the 
vaccine into the age-appropriate routine immunization schedule following an in-depth 
review of vaccine-related data, including data on disease epidemiology, vaccine efficacy and 
effectiveness, vaccine safety, feasibility of program implementation, and economic aspects 
of immunization policy [13]. However, even the largest pre-licensure trials are inadequate to 
assess the vaccine’s potential to induce rare adverse events. Therefore, post-licensure safety 
monitoring is critical because extremely rare serious adverse events (e.g., anaphylaxis), 
adverse events with delayed onset (e.g., Guillain Barré syndrome), or adverse events in 
specific subpopulations (e.g., pregnant women) are unlikely to be detected and assessed until 
the vaccine is more widely used in the population. Following licensure by FDA, and often 
along with recommendations by ACIP, vaccines are continuously monitored for safety by 
CDC and FDA (Fig. 1). FDA and CDC rely upon various post-licensure surveillance 
systems to detect and study adverse events that occur after immunizations, and further 
discussion will describe the approach and three of these systems in use by the CDC.
The CDC surveillance and research activities prioritize the safety evaluation of new vaccines 
and established vaccines where there has been a change in the recommendations (e.g., Tdap 
vaccine in pregnant women). A long-standing focus of the CDC research agenda is the 
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pharmacovigilance safety assessment of the annual seasonal influenza vaccines, which have 
traditionally been IIV3 (trivalent) vaccines, and these in some years have included strain 
changes to match the circulating viruses. In 2009, there was the novel pandemic H1N1 
monovalent vaccine. However, new influenza vaccines continue to be introduced 
(quadrivalent, high dose, adjuvanted, cell culture-based, and recombinant) and require rapid 
safety assessment through pharmacovigilance reports as well as epidemiologic studies to 
investigate any potential safety signals.
CDC uses three complementary systems to monitor and study the safety of US licensed 
vaccines (Table 1). These include the Vaccine Adverse Event Reporting System (VAERS), 
the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment 
(CISA) project. The VAERS is a national, spontaneous surveillance system co-managed 
with FDA, which receives more than 40,000 AE reports annually following all US licensed 
vaccines [14]. Healthcare providers, vaccine manufacturers, vaccine recipients, and the 
public can report to the VAERS, which serves as an “early warning” system and is useful for 
detecting rare, serious longer-term adverse events following immunization (AEFI), which 
may have gone undetected in pre-licensure human clinical trials. However, VAERS is 
subject to several limitations including under-reporting, reporting biases, inconsistent data 
quality and completeness, changes in reporting over time, and the lack of an unvaccinated 
comparison group. Consequently, VAERS data generally cannot establish if a vaccine caused 
a particular AEFI, including anaphylaxis. Thus, VAERS serves primarily for hypothesis 
generation, and once an AEFI signal is identified, this can be further studied in a more 
robust system such as the VSD.
The VSD is a collaboration between CDC and eight large integrated healthcare 
organizations, which has large linked databases containing vaccination records and health 
outcomes data from electronic medical records for a population of more than 12 million 
people (approximately 3% of US population), which are used for active surveillance and 
research [15]. A novel approach to expedite the timeliness of post-marketing safety 
monitoring in VSD is through rapid cycle analysis (RCA), which permits near “real-time” 
surveillance of pre-specified AEs for priority vaccines (e.g., annual seasonal influenza 
vaccines, newly licensed vaccines). Anaphylaxis is an outcome routinely included among 
these pre-specified AEs.
The CISA project is a collaboration of vaccine safety experts from the CDC’s Immunization 
Safety Office (ISO), seven academic medical research centers, and other partners [16]. The 
CISA project serves as a vaccine safety resource for US healthcare providers with complex 
vaccine safety questions about a specific patient to assist with immunization decision-
making; it also conducts clinical research to better understand vaccine safety and identify 
preventive strategies for AEFI and assists CDC and its partners in evaluating emerging 
vaccine safety issues. Although not discussed further, CISA project collaborators have 
recently authored several publications on anaphylaxis [6, 7, 17].
Brighton Collaboration Case Definition of Anaphylaxis
Standardized case definitions are crucial in epidemiologic studies as well as human clinical 
trials. In 2007, the Brighton Collaboration published a standardized surveillance case 
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definition for post-vaccination anaphylaxis [18]. In general, the Brighton Collaboration case 
definitions are considered as the gold standard surveillance case definitions for post-
vaccination AEs, including anaphylaxis. These criteria designate different levels of 
diagnostic certainty of the relevant AEFI and are proposed for use in vaccine clinical trials 
and safety surveillance and research studies. The Brighton Collaboration criteria are distinct 
from the more specific Second National Institute of Allergy Diseases (NIAID)/Food Allergy 
and Anaphylaxis (FAAN) criteria published in 2006, which are principally used for the 
clinical assessment of patients [19].
Anaphylaxis in VAERS
Recently, Su and colleagues reported the findings from their review of US reports of 
anaphylaxis received by VAERS during 1990–2016 [20•]. These investigators evaluated 
available data on reports describing symptom onset in the patient within 1 day of receiving 
vaccine, including a prior history of hypersensitivity, the type of vaccine(s) administered and 
assessed from the medical records whether the report met the Brighton Collaboration case 
definition for anaphylaxis or was diagnosed by a physician. During the 26-year study period, 
a total 828 reported cases were identified which either met the Brighton Collaboration case 
definition for anaphylaxis or were physician-diagnosed with anaphylaxis. The median age of 
the cases was 12 years (range, < 1 to 86); however, there were some differences between 
children and adults. Children aged < 19 years accounted for 478 reports, of which 65% were 
male. Of the total 828 case reports, 41% described persons with no history of 
hypersensitivity. There were also 8 death reports; in 7 of these anaphylaxis was identified as 
the cause of death, and in 6, there was rapid onset of symptoms (within 20 minutes) 
following vaccination suggesting vaccine exposure as the trigger (one report identified onset 
of fatal anaphylaxis within 2 minutes following concomitant receipt of trivalent influenza 
vaccine and intramuscular ceftriaxone in a penicillin allergic adult). The most commonly 
reported vaccines found associated with anaphylaxis in the VAERS review were influenza 
vaccines (all types, n = 330, 40%); however, among children, routine childhood vaccines 
(i.e., MMR, varicella, DTaP, Tdap) predominated, and among adults, influenza vaccine (all 
types) was the commonest vaccine type. Of note, among the 467 individuals who received 
only a single vaccine, the most commonly reported vaccine was influenza vaccine (all types; 
n = 254, [54%] reports).
These investigators commented that consistent with earlier studies, they found there was a 
preponderance of males in the younger age group and females in the older age group, 
symptom onset was rapid within 2 hours after vaccination, and the majority had a prior 
history of hypersensitivity including asthma and drug allergies [20•]. However, contrary to 
other studies, 41% of reports described no apparent history of hypersensitivity and more 
than 89% of reports indicated treatment with epinephrine, the first-line treatment for 
anaphylaxis. The study also identified rare anaphylaxis death reports, some without a prior 
history of hypersensitivity supporting the need for vaccine providers to be vigilant when 
administering all vaccines and prepared for immediate intervention, if needed.
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Anaphylaxis in VSD
A recent study in the VSD evaluated the risk of anaphylaxis after vaccination in children and 
adults [21]. The study used data on health plan enrollees who received 25,178,965 vaccine 
doses during the period January 2009–December 2011. These investigators used diagnostic 
and procedure codes to identify potential anaphylaxis cases, and then reviewed the medical 
records of the suspected cases to confirm the diagnosis, apply the Brighton Collaboration 
case definition for anaphylaxis, and determine the vaccine trigger. The study identified a 
total of 33 persons with anaphylaxis (Brighton level 1or 2) associated with vaccination for 
an estimated overall incidence of 1.31 per million vaccine doses administered; the incidence 
did not differ significantly by age, and there was a non-significant female predominance 
only among adults. IIIV3 (trivalent) vaccine accounted for 14 of the cases, for which the rate 
was estimated to be 1.59 per million vaccine doses and no cases occurred following 530,737 
LAIV doses. Twenty-eight (85%) cases had a prior history of atopy (anaphylaxis, asthma, or 
other specific allergies) [21]. This large population study also found no deaths among cases 
and no cases in children aged less than 4 years.
What the VAERS and VSD Studies Show
The VAERS and VSD studies summarized above provide complementary information from 
two of the CDC vaccine safety systems on anaphylaxis after vaccination. Both studies 
applied the Brighton Collaboration case definition for anaphylaxis and reviewed medical 
records (although the latter was less complete for VAERS). The VAERS review of 26 years 
of passive reports had a greater ability to identify cases (i.e., total 828 cases) whereas the 
VSD analysis allowed a more robust estimation of risk. Although these studies confirm its 
rarity after vaccination (1.3 cases per million vaccine doses administered), anaphylaxis can 
be a life-threatening event. Anaphylaxis after influenza vaccines is of particular concern 
because of the large number of persons vaccinated annually. Influenza vaccines are unique in 
requiring annual review and possibly changes in the vaccine’s antigenic composition to 
match the predicted circulating influenza strains. For this reason, vaccine safety surveillance 
systems specifically monitor for this outcome.
New Influenza Vaccines
Influenza vaccine manufacturing recently has become more varied (https://www.cdc.gov/flu/
prevent/how-fluvaccine-made.htm?). Until recently, the standard manufacturing process for 
influenza vaccines involved propagation of the vaccine virus strain(s) in embryonated hens’ 
eggs so that small amounts of residual ovalbumin were routinely included in these vaccines.
A recent innovation has been the introduction of cell-culture technology which involves 
propagating the viruses in mammalian (Madin-Darby canine kidney cells) in liquid culture 
rather than the traditional egg-based vaccine manufacturing process. Flucelvax® 
quadrivalent (ccIIV4; Seqirus) is manufactured using this process and approved for use in 
persons 4 years of age or greater. Through the current 2018–2019 US influenza season, one 
of the four vaccine viruses provided at the start of this vaccine’s manufacturing process has 
been egg-derived, so that egg proteins might still be present in the finished vaccine; however, 
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this might change for the 2019–2020 season vaccine to make the entire production process 
exclusively cell-based (https://www.prnewswire.com/news-releases/seqirus-announces-
further-advances-in-cell-based-influenza-vaccine-technology-300831979.html). Cell-based 
technology is more flexible than the traditional egg culture method and not reliant on an 
adequate egg supply; in addition, it has the potential advantage of a faster startup time in the 
event of a pandemic, and also the vaccine viruses are more similar to circulating influenza 
viruses because the virus grown in eggs can acquire egg-adapted changes that attenuate the 
vaccine’s protective efficacy.
Since 2013, a novel process for manufacturing influenza vaccine using recombinant 
technology has been approved. This manufacturing process has advantages including the 
potential for a faster start-up, which might represent an advantage in the event of a pandemic 
or vaccine supply shortage, mainly because it is not dependent on an egg supply or limited 
by the selection of vaccine viruses that are adapted for growth in eggs. In 2013, the FDA 
licensed the first recombinant HA influenza vaccine (Flublok®, Sanofi Pasteur) as a trivalent 
product, and the vaccine was subsequently recommended by the ACIP as an vaccine 
alternative for persons with egg allergy. For the 2018–2019 season, the vaccine is available 
as a quadrivalent formulation licensed for use in persons aged 18 years and above [11••]. 
The manufacturing process involves replication of influenza HA protein using insect cells 
and produces purified HA that contains no egg protein, preservatives, or antibiotics. 
Although free of egg protein, allergic reactions following Flublok® have been reported to 
VAERS among patients with a self-reported egg allergy or prior allergic reactions to IIV, 
although it is not known what triggered the reaction in these cases [22].
IIV3 (trivalent) vaccines which protect against 3 different viruses (influenza A H1N1 virus, 
influenza H3N2 virus, and 1 type B virus) have been the standard; however since 2013, to 
provide broader protection against circulating influenza viruses, IIV4 (quadrivalent) 
influenza vaccines, which contain 2 B strains in addition to 2 A strains, have been licensed 
and approved. Currently in the USA, there is an IIV4 (quadrivalent) product for all the 
influenza vaccines, with the exception of two vaccines targeted to protect the elderly 
(persons aged 65 years and older), (1) IIV3 (trivalent) HD (Fluzone® High-Dose, Sanofi 
Pasteur) vaccine with 4 times the amount of antigen contained in regular IIV3 (trivalent) 
vaccine, and (2) aIIV3 (Fluad,® Seqirus) vaccine formulated with the adjuvant MF59, which 
is recommended for adults aged 65 years and older. https://www.cdc.gov/flu/protect/vaccine/
how-fluvaccine-made.htm. Other new adjuvanted vaccines have been introduced for the 
prevention of herpes zoster and hepatitis B. To date, there has been no evidence from either 
pre-clinical or post-marketing data that anaphylaxis or other serious AEFIs are associated 
with any of the new adjuvanted vaccines. Despite some increased reactogenicity, there has 
been vigorous uptake of both aIIV3 and RZV (Shingrix® GlaxoSmithKline) vaccines; 
however to date, the use of new hepatitis B vaccine (recombinant) (Heplisav-B®, Dynavax) 
vaccine has been quite limited. Post-marketing data from the VAERS for the aIIV3 vaccine 
found only commonly reported symptoms of fever, injection site pain, and injection site 
erythema, but no unexpected patterns or serious AEFIs were detected, and the overall 
assessment was consistent with the safety profile observed in pre-licensure clinical trials 
[23].
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In summary, pharmacovigilance and epidemiologic studies conducted in large populations 
receiving currently used vaccines, confirm the rarity of post-vaccination anaphylaxis. 
Continuous monitoring of all new vaccines for safety using post-marketing, large-linked, 
data surveillance systems is routinely conducted by CDC and FDA; and anaphylaxis is 
included among the pre-specified outcomes monitored. Vaccine manufacturing processes 
have become more diverse, particularly for influenza vaccines (higher antigen, cell cultured, 
recombinant, and adjuvanted); of these, recombinant influenza vaccine is free of egg protein, 
which offers an additional option for persons with egg allergy. Providers should be aware of 
changing recommendations based on recent published evidence for persons with a history of 
egg allergy to receive annual influenza vaccination. Although anaphylaxis after 
immunization is rare, its immediate onset (usually within minutes) and life-threatening 
nature require that all personnel and facilities providing vaccinations be prepared to treat 
possible anaphylactic reactions.
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Fig. 1. 
The vaccine life cycle
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